Abstract
AIM: This systematic literature review summarizes the real-world effectiveness, safety, and tolerability of avelumab first-line maintenance (1LM) in locally advanced or metastatic urothelial carcinoma (la/mUC). MATERIALS & METHODS: Database searches (MEDLINE, Embase, Cochrane) and manual gray literature searches of real-world studies published from 01/01/2020-31/01/2024 were performed. Pooled 12-month overall survival (OS) and progression-free survival (PFS) rates were synthesized by meta-analysis. RESULTS: Across 45 unique studies including >2,600 patients, median OS and PFS were 21.3 and 7.0 months, respectively. In the meta-analysis, 12-month OS and PFS rates (95% CI) from avelumab 1LM start were 69% (65-73%) and 39% (35-44%), respectively. CONCLUSION: This study supports the established clinical benefit of avelumab 1LM across a broad range of patients with la/mUC in routine practice.